A prospective study of the removal rate of imaged breast lesions by an 11-gauge vacuum-assisted biopsy probe system
Section snippets
Methods
This was an open, prospective, single-center study. From September 1999 to November 1999, women referred to The Breast Center with breast lesions visualized by mammography or ultrasonography qualified for voluntary enrollment in the study if they were at least 18 years of age, not pregnant, not lactating, and did not have prosthetic breast implants. Qualifying patients who had given written informed consent were then scheduled for the biopsy and a 6-month follow-up visit.
Prior to the biopsy,
Results
Forty-six patients were enrolled in the study. One patient had the scheduled biopsy performed with a nonstudy device and was therefore discontinued from the study. That patient’s data were not included in the summary analysis.
The 45 evaluable patients ranged in age from 23 to 75 years with a mean age of 47.4 years. The patients were predominately Caucasian (89%); 4 blacks (9%) and 1 Asian/Pacific Islander (1%) were also included in the study population. Of the 45 evaluable patients, 33 (73%)
Comments
Innovative technology has now combined stereotactic or ultrasonography imaging with a minimally invasive biopsy system for the diagnosis of nonpalpable lesions identified by mammogram or sonogram. Using the Mammotome breast biopsy system, a diagnosis can be made through a single, sutureless incision, avoiding an open surgical biopsy. This vacuum-assisted biopsy device has the potential to completely remove the image evidence of the lesion at the time of the initial diagnostic biopsy procedure.
Conclusion
Minimally invasive percutaneous image-guided breast biopsy is becoming a more widely accepted method to diagnose the abnormal lesions that can be visualized with mammography or ultrasonography. Many physicians performing these procedures prefer that the imaged evidence of the lesion be removed to potentially increase accuracy in biopsy and follow-up, and provide reassurance to the patient that the lesion in question has been adequately sampled. This study demonstrates that complete removal of
References (13)
- et al.
The evolving practice pattern of the breast surgeon with disappearance of open biopsy for nonpalpable lesions
Am J Surg
(1998) - et al.
Complete removal of nonpalpable breast malignancies with a stereotactic percutaneous vacuum-assisted biopsy instrument
J Am Coll Surg
(1999) - et al.
Cancer statistics, 2000
CA Cancer J Clin
(2000) The positive predictive value of mammography
AJR Am J Roentgenol
(1992)- et al.
Stereotactic core-needle biopsy of the breasta report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American Pathologists
CA Cancer J Clin
(1997) - et al.
Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy
Radiology
(1998)
Cited by (53)
Vacuum-assisted excision of small breast cancers under ultrasound guidance
2023, European Journal of RadiologyThe SMALL Trial: A Big Change for Small Breast Cancers
2019, Clinical OncologyPercutaneous excisional biopsy of clinically benign breast lesions with vacuum-assisted system: Comparison of three devices
2012, European Journal of RadiologyCitation Excerpt :In the past 10 years, minimally invasive breast biopsy system has gotten great development. As a kind of minimally invasive method, vacuum-assisted system provides a new choice for excision of benign breast lesions and has been demonstrated to be successfully applied in excision of benign breast lesions by previous studies [4–15] (Table 6). The Vacora®, Mammotome® and the EnCor® devices are three vacuum-assisted systems currently on the market.
Percutaneous excision: A viable alternative to manage benign breast lesions
2011, Canadian Association of Radiologists JournalPatient satisfaction and efficacy of vacuum-assisted excision biopsy of fibroadenomas
2009, Clinical RadiologyCitation Excerpt :There was no correlation between the gauge of needle used and the rate of recurrence in the present study, although the vast majority of lesions were removed using the larger gauge. Previous studies have suggested that VAB is effective at removing smaller fibroadenomas (<15 mm), but less successful at removing larger lesions,26 which are also more likely to recur after 6 months.27 Indeed, some authors claim that excision by VAB is not suitable for lesions over 20 mm in diameter.18